Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency
22 Aug 2019
FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA
Mundipharma announces exclusive license and supply agreement with Prestige Biopharma for Tuznue® (HD201)
2 Jul 2019
FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY
Invokana® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis
11 Jun 2019
STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY
Mundipharma announces exclusive outsourcing distribution agreement with Egis Pharmaceuticals for Pelmeg▼® in Central and Eastern Europe
13 May 2019
FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY
Invokana® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study
16 Apr 2019
EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY
Mountain rescue study launches to investigate use of Penthrox® (methoxyflurane) for trauma-related pain in hostile environments
27 Mar 2019
FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY
Mundipharma Announces Launch of INVOKANA® and VOKANAMET® in Norway for the Treatment of Type 2 Diabetes as Part of Exclusive Distribution Agreement with Janssen
19 Mar 2019
FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY
Mundipharma opens its doors to local schools to inspire the next generation of scientists
13 Mar 2019
FOR LOCAL MEDIA ONLY
Mundipharma wins 1st ever PLG deal of the year award for acquisition of Cinfa Biotech
26 Feb 2019
Mundipharma appoints Patrice Grand as European Director of Corporate Communications
19 Feb 2019
FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY
Mundipharma launches Pelmeg®▼(pegfilgrastim) biosimilar in Europe
7 Feb 2019
PAN-EU RELEASE FOR DISTRIBUTION TO MEDICAL AND BUSINESS OUTLETS ONLY
Mundipharma announces Marco Cerato as Senior Vice President Business Development and Strategic Partnerships
30 Nov 2018
FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY
European Commission approves Pelmeg▼® (pegfilgrastim) as a biosimilar treatment to reduce the duration of neutropenia and incidence of febrile neutropenia in adults treated with chemotherapy
23 Nov 2018
FOR EUROPEAN MEDICAL MEDIA ONLY
Mundipharma announces Chief Financial Officer
19 Nov 2018
FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY
flutiform® receives a positive opinion in Europe for the Treatment of Children with Asthma
7 Nov 2018
FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA
New guidance from ADA and EASD recommends use of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for patients with type 2 diabetes
16 Oct 2018
FOR EU MEDICAL MEDIA ONLY, NOT FOR DISTRIBUTION TO US MEDIA
Mundipharma strengthens position as a leader in biosimilars with acquisition of development company Cinfa Biotech
10 Oct 2018
FOR BUSINESS AND TRADE MEDIA ONLY
Mundipharma announces Philippe Bastide as Head of Biosimilars
5 Oct 2018
FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY
flutiform® k-haler®, a Novel Treatment for Adolescents and Adults with Asthma, now Available in Europe
10 Sep 2018
FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA
European Commission expands labelling for INVOKANA® and VOKANAMET® to include positive data on cardiovascular and renal outcomes
7 Sep 2018
FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY
Innovative pharmaceutical pricing agreements preferable to discounts, according to new European payer survey
21 Aug 2018
FOR EUROPEAN MEDICAL/TRADE MEDIA ONLY
Pharmaceutical market access in Europe, by Will Dunlop
16 Aug 2018
EUROPEAN TRADE/MEDICAL MEDIA ONLY
The CHMP issues positive opinion to expand INVOKANA® and VOKANAMET® labels to include positive data on cardiovascular and renal outcomes
2 Aug 2018
INFORMATION FOR EUROPEAN MEDICAL/TRADE ONLY
Mundipharma International welcomes positive phase III efficacy findings for Invokana® (canagliflozin) in type 2 diabetes patients with chronic kidney disease
20 Jul 2018
INFORMATION FOR EUROPEAN MEDICAL/TRADE MEDIA ONLY
What the patient access experts are saying
18 Jun 2018
BY WILL DUNLOP, HEAD OF MARKET ACCESS, MUNDIPHARMA INTERNATIONAL
